What initial therapy should be started for a 32‑year‑old woman at 26 weeks gestation with a confirmed right lower‑extremity deep‑vein thrombosis (DVT)?

Anticoagulation for Acute DVT in Pregnancy

Low-molecular-weight heparin (LMWH) should be initiated immediately at therapeutic weight-based doses for this 32-year-old woman at 26 weeks gestation with confirmed right lower extremity DVT. 1

Primary Recommendation

The American Society of Hematology issues a strong recommendation (Grade 1B) to use LMWH over unfractionated heparin (UFH) for pregnant women with acute venous thromboembolism, supported by moderate-certainty evidence. 1 This recommendation is echoed by the American College of Chest Physicians (Grade 1B) 1 and the European Society of Cardiology, which designates LMWH as the drug of choice for VTE treatment during pregnancy. 1

Why LMWH is Superior to Alternatives

LMWH offers multiple advantages over UFH in the pregnant patient:

• Reduced heparin-induced thrombocytopenia (HIT) risk: The incidence is markedly lower with LMWH (0% in pregnancy cohorts) compared to UFH (2.7% in non-pregnant populations). 2
• Minimal osteoporosis risk: Only 0.04% incidence with LMWH versus 2.2% with extended UFH use. 2
• Superior efficacy: Recurrent VTE rates during pregnancy with LMWH treatment are only 1.15-1.97%. 2, 3
• Better bioavailability and convenience: Once or twice daily subcutaneous dosing without routine laboratory monitoring. 1, 2

Dosing Regimen

Either once-daily or twice-daily therapeutic LMWH dosing is acceptable (conditional recommendation). 1

• Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 1, 2
• Dalteparin: 100 IU/kg subcutaneously twice daily 1

Weight-based therapeutic dosing is essential—prophylactic doses are inadequate for acute DVT treatment. 2

Monitoring

Routine anti-factor Xa level monitoring is NOT recommended for most pregnant women receiving therapeutic LMWH. 1, 2 The American Society of Hematology makes a conditional recommendation against routine anti-Xa monitoring to guide dosing, citing low-certainty evidence. 1

Absolutely Contraindicated Therapies

Warfarin is absolutely contraindicated throughout pregnancy due to teratogenicity (particularly in the first trimester), risk of fetal bleeding, and potential neurodevelopmental deficits. 1, 2

All direct oral anticoagulants (DOACs)—including rivaroxaban, apixaban, edoxaban, and dabigatran—are absolutely contraindicated in pregnancy because they cross the placental barrier and their reproductive effects in humans are unknown. 2

Duration of Therapy

Anticoagulation must be continued throughout the remainder of pregnancy and for at least 6 weeks postpartum, with a minimum total duration of 3 months from the time of DVT diagnosis. 1, 2 This is critical because the first 6 weeks postpartum carry the highest thrombotic risk. 2

Peripartum Management

LMWH should be discontinued at least 24 hours before planned delivery or neuraxial anesthesia to reduce bleeding risk while maintaining thromboprophylaxis. 1, 2 After delivery, anticoagulation should be resumed and continued for the full postpartum period. 1

Postpartum Options

After delivery, acceptable anticoagulation options include:

• Prophylactic or intermediate-dose LMWH (Grade 2B recommendation) 1
• Warfarin targeting INR 2.0-3.0 1
• LMWH, UFH, and warfarin are all considered safe during breastfeeding and may be continued without interruption. 1, 2

Special Circumstances Requiring UFH Instead

UFH may be preferred over LMWH only in these specific situations:

• Severe renal impairment (creatinine clearance <30 mL/min), as LMWH accumulates renally and markedly increases bleeding risk 2
• History of heparin-induced thrombocytopenia: In this case, neither LMWH nor UFH should be used; alternatives such as danaparoid or fondaparinux (with caution) should be substituted 4, 2

Critical Pitfalls to Avoid

• Do NOT use prophylactic doses for acute DVT treatment—therapeutic weight-based dosing is required. 2
• Do NOT delay treatment while awaiting additional diagnostic confirmation if clinical suspicion is high. 2
• Do NOT discontinue anticoagulation prematurely in the postpartum period—the full 6-week postpartum course is essential. 2
• Do NOT switch to oral anticoagulants during pregnancy, even if the patient was previously stable on them. 2
• Do NOT use LMWH in patients with prior HIT due to up to 90% cross-reactivity with heparin antibodies. 4